Search Results

Agilent Technologies Inc. (NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF.

Kick-off meetings have taken place in all academic sites that will be participating in the pivotal validation plan towards regulatory approvals of iBiopsy® LCS CADe/CADx SaMD.

PreOmics Introduces New ENRICH-iST Kits and Novel Workflow for Unbiased, Affordable Plasma and Serum Proteomics by LC-MS.

GC Cell, a fully integrated cell therapy pioneer has announced a strategic partnership with BioCentriq, a cell therapy contract development and manufacturing organization (CDMO) and US affiliate of GC Cell.

Reneo Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted mavodelpar Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long-chain fatty acid oxidation disorder (LC-FAOD).

Revive Therapeutics Ltd. announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive LC POC Lateral Flow Test Kit.

Precision Medicine Asia Co., Ltd. and National Cancer Center Hospital East announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific, a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.

Revive Therapeutics Ltd. announced today an update on the meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) of the Revive LC POC Lateral Flow Test Kit (the “Product”) for feedback on the classification, development and regulatory submission strategy for a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions.